Video & Transcript Research : 'HB454'

LA

Louisiana 2026 Regular Session

House of Representatives May 6th, 2026

Louisiana House Floor Meeting

Bills: HR244, HR245, HR246, HR247, HR248, HR249, HR250, HR251, HCR101, HCR102, HR223, HR224, HR225, HR226, HR227, HR229, HR230, HR231, HR232, HR234, HR235, HR236, HR237, HR238, HR239, HR240, HR241, HR242, HR243, HCR94, HCR95, HCR96, HCR97, HCR98, HCR99, HCR100, SCR31, SCR33, SCR35, SCR37, SCR56, SCR57, SB171, SB251, SB252, SB353, SB367, SB433, SB461, HR170, HR191, HR206, HR207, HR208, HR217, HCR11, HCR53, HCR60, HCR66, HCR68, HB66, HB153, HB165, HB326, HB387, HB454, HB455, HB484, HB513, HB603, HB660, HB719, HB762, HB766, HB793, HB802, HB816, HB833, HB940, HB947, HB950, HB975, HB1028, HB1039, HB1051, HB1053, HB1080, HB1201, HB1215, HB1228, HB1251, HB1252, SCR2, SB26, SB28, SB29, SB30, SB41, SB44, SB64, SB84, SB87, SB93, SB98, SB107, SB118, SB142, SB192, SB195, SB199, SB219, SB222, SB234, SB241, SB255, SB275, SB277, SB292, SB294, SB306, SB314, SB482, SB233, SB326, HR171, HCR49, HCR65, HCR72, HR37, HCR64, SCR19, SCR3, SCR6, SCR18, SCR11, SCR22, HB64, HB68, HB92, HB130, HB258, HB633, HB801, HB89, HB341, HB451, HB456, HB579, HB595, HB621, HB818, HB841, HB1064, HB1101, HB1191, SB47, SB82, SB106, SB206, SB210, SB248, SB305, SB376, SB397, SB441, SB2, SB19, SB24, SB50, SB70, SB96, SB101, SB103, SB104, SB114, SB122, SB159, SB160, SB173, SB180, SB182, SB260, SB412, SB418, SB424, SB442, SB460, SB476, SB1, SB23, SB32, SB42, SB43, SB46, SB51, SB110, SB113, SB150, SB154, SB161, SB218, SB220, SB221, SB253, SB289, SB310, SB351, SB399, SB404, SB502, HCR32, HB955, HB284, HB617, HB730, HB926, HB1125, HB1194, HB1203, HB798, HB998, HB1084, HB1223, HB646, HB824, HB901, HB79, HR20, HR74, HB59, HB306, HB366, HB393, HB458, HB577, HB582, HB605, HB614, HB682, HB733, HB752, HB773, HB911, HB996, HB1035, HB1069, HB1113, HB1140, HB1180, HB1234, HB1240, SB89, SB68, SB149
HI

Hawaii 2025 Regular Session

Senate Floor Session 04-04-2025 11:30am

Hawaii Senate Floor Meeting

Transcript Highlights:
  • <00:08:25.319> HB454 no votes? 25 eyes. Thank you. HB454 no votes? 25 eyes. Thank you.
  • HB454 HD2SD1<00:08:27.599> passes.<00:08:28.080> Third<00:08:28.400> reading.
Keywords: 912, senate, all
AL

Alabama 2025 Regular Session

Alabama House Apr 22nd, 2025

Alabama House Floor Meeting

NH
Transcript Highlights:
  • <01:06:36.160> Um<01:06:36.960> HB454 Moving right along. All right.
  • Um HB454 Moving right along. All right.
  • Um HB454 requiring<01:06:38.799> retailers<01:06:39.280> of<01:06:39.520> fuel<01
Keywords: 928, house, all
Summary: The committee began by discussing 15 retained bills and the chair’s preference to keep them alive through interim study rather than kill them, using them as vehicles for further discussion and possible later amendments. The chair said the bills would be executed out by November and then move to the House floor in January, and members generally agreed that interim study was the prevailing motion for the retained bills. Several health-related bills were then discussed. On Senate Bill 247, concerning pharmacy network exclusion when PBM reimbursement is below acquisition cost, members said the issue had been presented differently in prior discussions and noted unfamiliar intermediaries such as PSAOs; the bill was viewed as too complex to resolve immediately, so interim study was favored. A bill on treatment alternatives to opiates was said to need an amendment from the Insurance Department, and a bill on self-funded employer access to claims data was described as having changed substantially through amendment; the sponsor explained it was intended to incentivize self-funded plans to opt into the state’s all-payer claims database (CHIS) so their data could be used for cost analysis, and members indicated a separate bill would be brought later. The committee spent the most time on a glucose monitoring bill, with testimony from a sponsor and a parent of a type 1 diabetic describing the medical benefits of continuous glucose monitors, especially for preventing dangerous lows and managing fluctuations. Opponents and committee members raised concerns about the cost of a mandate, the effect on premiums in the individual and small-group markets, and whether the bill should require coverage without a prescription; one member cited medical literature suggesting limited evidence for non-insulin users. The chair concluded the bill was headed to interim study and said the committee would do further homework on the economic impact, especially for type 1 coverage. The meeting then moved on to a bill about insurer audits and clawbacks, where the Insurance Department commissioner explained that the issue involved several separate provider-payment problems that had recently come to the department’s attention and that the department would provide a report and work with the sponsor on next steps.